Skip to content

Hypertonic Saline in Acute Bronchiolitis

Hypertonic Saline in Acute Bronchiolitis: a Randomised controlled trial and Economic evaluation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN31128055
Enrollment
300
Registered
2011-05-23
Start date
2011-10-15
Completion date
Unknown
Last updated
2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute bronchiolitis Respiratory Acute bronchiolitis

Interventions

Nebulised 3% hypertonic saline will be administered 6 hourly in the intervention group, in addition to standard supportive care, until the infant meets the pre-set criteria for discharge. A single use
driven by piped oxygen will be used to administer the hypertonic saline. The control arm will receive standard supportive care. Total duration of follow-up will be 28 days from entry

Sponsors

Sheffield Children's NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Previously healthy infants under 1 year of age admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition.

Exclusion criteria

Exclusion criteria: 1. Wheezy bronchitis or asthma ? children with an apparent viral respiratory infection and wheeze with no or occasional crepitations 2. Previous lower respiratory tract infections 3. Risk factors for severe disease (gestation < 32 weeks, immunodeficiency, neurological and cardiac conditions) 4. Participation in another study involving investigational medication 5. Subjects where the carer?s English is not fluent and translational services are not available 6. Requiring admission to high dependency or intensive care units at the time of recruitment

Design outcomes

Primary

MeasureTime frame
Current primary outcome measures as of 27/10/2011: 1. Time to ?fit for discharge?, which will be judged to be when the infant is feeding adequately (taking more than 75% of usual intake) 2. Has been in air with a saturation of at least 92% for 6 hours, to reflect clinical practice. Previous primary outcome measures: 2. Has been in air with a saturation of 94% or greater for 12 hours

Secondary

MeasureTime frame
1. Actual time to discharge 2. Readmission within 28 days from randomisation 3. Health care utilisation, post-discharge and within 28 days from randomisation 4. Duration of respiratory symptoms post discharge and within 28 days from randomisation 5. Infant and parental quality of life using the Infant Toddler Quality of Life (ITQoL) questionnaire at 28 days following randomisation.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026